Astrid Borkowski

Astrid Borkowski, M.D., Ph.D., is Chief Medical Officer at HilleVax. Astrid has more than 20 years of experience in vaccine development, spanning all development phases, global filing, approval, and post marketing stages, as well as Medical Affairs for pre-and post-marketing activities. Astrid’s most recent role was VP, Head of Clinical Development at the Takeda’s Vaccine Business Unit where she oversaw the clinical development of all vaccine assets, including HIL-214.

Prior to joining Takeda, Astrid was Chief Medical Officer responsible for the European Region and later led early viral and bacterial vaccine development at Novartis Vaccines. In her roles prior to Novartis Vaccines, she was responsible for the pandemic influenza vaccine clinical development at GSK, and worked on meningococcal and seasonal influenza vaccine development during her time at Chiron Vaccines.

Astrid completed her Medical Degree at the Humboldt University in Berlin, Germany, from which she also received her Ph.D. in Immunology. She trained in internal medicine/rheumatology before completing her postdoctoral studies at the Mayo Clinic, Rochester, MN.